H. Lundbeck A/S, the Danish specialist in brain diseases, reported a 9.8% rise in second quarter revenue to DKK 4.7 billion (€631 million) while its operating profit rose by 21.7% in the period to DKK 1.66 billion. The buoyant results were attributed to large increases in sales of the company’s schizophrenia, major depression and hypotension drugs. However the effect of price rises, if any, was not disclosed.
For the first half year, Lundbeck’s revenue rose by 9.3% to nearly DKK 9.3 billion while its operating profit increased by 34% to DKK 3.5 billion.